Aurinia Pharmaceuticals Inc. (AUPH) Tuesday said the U.S. Food and Drug Administration has approved a label update for LUPKYNIS, the company's approved medicine for the treatment of adult patients with active lupus nephritis (LN).
The label now includes three-year data from the AURORA 2 extension study which showed sustained complete renal response with LUPKYNIS through three years. The updated label does not state that the safety and efficacy of LUPKYNIS has not been established beyond one year.
The label also indicates that monthly kidney function assessment is no longer required after first year of treatment. The label had previously stated that it should be assessed every four weeks for the duration of treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.